AI in Drug Discovery 2026: What Actually Works, What Remains Hype, and Where the IP Value Sits
The Cost Structure That Makes AI Non-Optional Bringing a New Molecular Entity (NME) to market costs, on average, US $2.8 […]
The Pharmacy of the World at a Crossroads: Navigating Challenges and Embracing a New Era of Global Leadership in Indian Pharma
1. Executive Strategic Overview The Indian pharmaceutical industry, historically celebrated as the “Pharmacy of the World” for its unparalleled capacity
Generic Drug Market Entry: The Complete Analyst’s Playbook for Patent Cliff Profits
1. The Opportunity in Numbers: Patent Cliff Sizing and Market Structure Global Market Scale and Growth Trajectory The global generic
Generic Drug Market Entry: The Complete Analyst’s Playbook for Patent Cliff Profits Read Post »
How to FOIA an IND Application: The Complete Pharma Intelligence Playbook
For IP teams, portfolio managers, competitive intelligence leads, and institutional investors who need to know what the FDA is holding
How to FOIA an IND Application: The Complete Pharma Intelligence Playbook Read Post »
Generic Drug Market Entry: The Complete Patent Expiry, ANDA Strategy, and IP Valuation Playbook
1. Why Generic Drug Market Entry Demands a Different Analytical Framework Generic pharmaceutical market entry is not a standard product
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors operating in or entering the Russian market. 1. Why
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook Read Post »
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy
I. Why This Document Exists Every blockbuster drug that has generated a billion-dollar revenue stream in the past three decades
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy Read Post »
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs
In the early months of the pandemic, when much of the economy was idling, an unusual silence fell over another
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Generic Drug Repurposing: The Complete IP, Regulatory, and Licensing Playbook for Off-Patent Assets
Off-patent drugs represent one of the most systematically underexploited categories in the pharmaceutical IP landscape. Their pharmacology is known. Their
